Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLPT NASDAQ:CNXU NASDAQ:DCTH NASDAQ:HSDT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLPTClearPoint Neuro$13.30+7.5%$10.88$8.27▼$30.10$370.97M1.31628,055 shs737,068 shsCNXUConexeu Sciences$16.85+0.1%$0.00$10.87▼$18.79$425.80MN/A115,778 shs154,266 shsDCTHDelcath Systems$10.33-1.9%$10.52$8.12▼$17.35$363.51M0.54501,063 shs396,578 shsHSDTSolana$1.48-7.5%$2.04$1.46▼$178.50$93.42M1.06299,041 shs568,998 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLPTClearPoint Neuro+7.52%+15.65%+16.97%+43.78%+5.06%CNXUConexeu Sciences+0.06%+23.62%+1,684,999,900.00%+1,684,999,900.00%+1,684,999,900.00%DCTHDelcath Systems-1.90%-5.32%-4.35%+13.77%-35.76%HSDTSolana-7.50%-33.93%-30.19%-34.22%-99.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLPTClearPoint Neuro$13.30+7.5%$10.88$8.27▼$30.10$370.97M1.31628,055 shs737,068 shsCNXUConexeu Sciences$16.85+0.1%$0.00$10.87▼$18.79$425.80MN/A115,778 shs154,266 shsDCTHDelcath Systems$10.33-1.9%$10.52$8.12▼$17.35$363.51M0.54501,063 shs396,578 shsHSDTSolana$1.48-7.5%$2.04$1.46▼$178.50$93.42M1.06299,041 shs568,998 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLPTClearPoint Neuro+7.52%+15.65%+16.97%+43.78%+5.06%CNXUConexeu Sciences+0.06%+23.62%+1,684,999,900.00%+1,684,999,900.00%+1,684,999,900.00%DCTHDelcath Systems-1.90%-5.32%-4.35%+13.77%-35.76%HSDTSolana-7.50%-33.93%-30.19%-34.22%-99.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLPTClearPoint Neuro 2.33Hold$18.0035.34% UpsideCNXUConexeu Sciences 0.00N/AN/AN/ADCTHDelcath Systems 2.43Hold$22.50117.81% UpsideHSDTSolana 2.50Moderate Buy$3.50136.49% UpsideCurrent Analyst Ratings BreakdownLatest HSDT, CLPT, DCTH, and CNXU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026DCTHDelcath Systems Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/11/2026DCTHDelcath Systems Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/8/2026CLPTClearPoint Neuro Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.004/27/2026HSDTSolana Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/23/2026HSDTSolana B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$3.004/22/2026HSDTSolana B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026HSDTSolana Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CLPTClearPoint Neuro Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026HSDTSolana Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold ➝ Buy$4.003/18/2026CLPTClearPoint Neuro B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $20.003/5/2026CLPTClearPoint Neuro B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$28.00 ➝ $18.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLPTClearPoint Neuro$36.97M10.79N/AN/A$0.99 per share13.43CNXUConexeu SciencesN/AN/AN/AN/AN/AN/ADCTHDelcath Systems$85.23M4.18$0.05 per share201.44$3.15 per share3.28HSDTSolana$6.02M14.36N/AN/A$6.88 per share0.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLPTClearPoint Neuro-$25.54M-$1.01N/AN/AN/A-71.57%-140.96%-36.98%8/11/2026 (Estimated)CNXUConexeu SciencesN/AN/AN/AN/AN/AN/AN/AN/AN/ADCTHDelcath Systems$2.70M$0.011,033.00N/AN/A0.62%0.51%0.46%8/5/2026 (Estimated)HSDTSolana-$40.89M-$109.67N/AN/AN/A-1,427.15%-67.57%-24.09%8/13/2026 (Estimated)Latest HSDT, CLPT, DCTH, and CNXU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026HSDTSolana-$0.34-$1.30-$0.96-$1.30$3.40 million$3.62 million5/13/2026Q1 2026CLPTClearPoint Neuro-$0.28-$0.32-$0.04-$0.32$11.97 million$12.13 million5/7/2026Q1 2026DCTHDelcath Systems-$0.0971-$0.03+$0.0671-$0.03$23.51 million$24.99 million3/31/2026Q4 2025HSDTSolana-$26.50$4.25+$30.75$4.25$0.14 million$5.23 million3/17/2026Q4 2025CLPTClearPoint Neuro-$0.22-$0.27-$0.05-$0.27$10.40 million$10.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLPTClearPoint NeuroN/AN/AN/AN/AN/ACNXUConexeu SciencesN/AN/AN/AN/AN/ADCTHDelcath SystemsN/AN/AN/AN/AN/AHSDTSolanaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLPTClearPoint Neuro2.635.794.88CNXUConexeu SciencesN/AN/AN/ADCTHDelcath SystemsN/A11.2410.33HSDTSolanaN/A9.909.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLPTClearPoint Neuro30.08%CNXUConexeu SciencesN/ADCTHDelcath Systems61.12%HSDTSolana18.63%Insider OwnershipCompanyInsider OwnershipCLPTClearPoint Neuro6.94%CNXUConexeu SciencesN/ADCTHDelcath Systems19.36%HSDTSolana14.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLPTClearPoint Neuro11029.99 million27.91 millionOptionableCNXUConexeu Sciences425.27 millionN/AN/ADCTHDelcath Systems6034.52 million27.84 millionOptionableHSDTSolana3058.39 million49.98 millionNot OptionableHSDT, CLPT, DCTH, and CNXU HeadlinesRecent News About These CompaniesSolana Company Expands ATM Equity Offering CapacityMay 29, 2026 | tipranks.comSolana (HSDT) Q4 2025 Earnings TranscriptMay 27, 2026 | finance.yahoo.comSolana Company Reconfigures Board and Audit OversightMay 22, 2026 | tipranks.comSolana Company Earnings Call Balances Growth and RiskMay 20, 2026 | tipranks.comSolana (HSDT) Q1 2026 Earnings TranscriptMay 19, 2026 | finance.yahoo.comSolana Company targets Pacific Backbone nodes operational in late June after $8M raise at $2.60 per shareMay 16, 2026 | msn.comSolana Company (HSDT) Q1 2026 Earnings Call TranscriptMay 15, 2026 | seekingalpha.comSolana Q1 Earnings Call HighlightsMay 15, 2026 | marketbeat.comSolana Company Reports First Quarter 2026 Financial ResultsMay 15, 2026 | financialpost.comFSolana Company Reports First Quarter 2026 Financial ResultsMay 15, 2026 | globenewswire.comSolana Company to Release First Quarter 2026 Operating Results on May 15, 2026May 11, 2026 | financialpost.comFSolana Company to Release First Quarter 2026 Operating Results on May 15, 2026May 11, 2026 | globenewswire.comJito Foundation and Solana Company Announce Strategic Partnership to Enhance Institutional Adoption of Solana in APAC RegionMay 6, 2026 | quiverquant.comQJito Foundation and Solana Company (NASDAQ: HSDT) Announce Strategic Partnership to Expand Institutional Solana Infrastructure Across Asia-Pacific RegionMay 6, 2026 | financialpost.comFJito Foundation and Solana Company (NASDAQ: HSDT) Announce Strategic Partnership to Expand Institutional Solana Infrastructure Across Asia-Pacific RegionMay 6, 2026 | globenewswire.comSolana (HSDT) price target decreased by 12.50% to 3.57April 28, 2026 | msn.comSolana Company Strengthens Board with Crypto Finance ExpertsApril 27, 2026 | theglobeandmail.comSolana Company raises $8M through stock offeringApril 27, 2026 | ca.investing.comSolana Company Raises Capital in Structured Equity OfferingApril 27, 2026 | tipranks.comSolana Company (NASDAQ: HSDT) Announces Registered Direct Offering of Common Stock to Global Institutional InvestorApril 27, 2026 | globenewswire.comSolana Company Announces Chief Medical Officer ResignationApril 13, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHSDT, CLPT, DCTH, and CNXU Company DescriptionsClearPoint Neuro NASDAQ:CLPT$13.30 +0.93 (+7.52%) Closing price 06/3/2026 04:00 PM EasternExtended Trading$13.36 +0.05 (+0.41%) As of 06/3/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Conexeu Sciences NASDAQ:CNXU$16.85 +0.01 (+0.06%) Closing price 06/3/2026 04:00 PM EasternExtended Trading$16.75 -0.10 (-0.59%) As of 06/3/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University's right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company's only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix ("ECM") formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the "10 Minute Tissue™" concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration ("FDA") clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.Delcath Systems NASDAQ:DCTH$10.33 -0.20 (-1.90%) Closing price 06/3/2026 04:00 PM EasternExtended Trading$10.20 -0.13 (-1.21%) As of 06/3/2026 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Solana NASDAQ:HSDT$1.48 -0.12 (-7.50%) Closing price 06/3/2026 04:00 PM EasternExtended Trading$1.52 +0.04 (+2.64%) As of 06/3/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coke's $10B India IPO Plan Pops the Top on Hidden Value Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test FedEx Unboxes Billions in Post-Spinoff Value Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
